Aptorum Group (NASDAQ:APM) Stock Price Down 4.6% – What’s Next?

Posted by Mark Dietrich on Aug 7th, 2026

Shares of Aptorum Group Limited (NASDAQ:APM – Get Free Report) dropped 4.6% during trading on Thursday . The company traded as low as $0.60 and last traded at $0.6680. Approximately 167,078 shares changed hands during mid-day trading, an increase of 188% from the average session volume of 57,956 shares. The stock had previously closed at $0.70.

Analysts Set New Price Targets

Separately, Weiss Ratings raised Aptorum Group from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Thursday, July 16th. One investment analyst has rated the stock with a Sell rating, According to data from MarketBeat.com, the company currently has a consensus rating of “Sell”.

Check Out Our Latest Stock Analysis on Aptorum Group

Aptorum Group Stock Down 4.6%

The stock has a 50 day moving average of $6.43 and a 200 day moving average of $7.90.

Aptorum Group Company Profile

(Get Free Report)

Aptorum Group Ltd. (NASDAQ: APM) is a global biopharmaceutical company incorporated under the laws of the Cayman Islands and headquartered in Hong Kong. Since its Nasdaq listing in 2018, the company has focused on the discovery, development and commercialization of novel therapeutics and diagnostic products. Aptorum’s research efforts are aimed at addressing unmet medical needs across oncology, metabolic disorders, infectious diseases and neurological conditions.

The company’s diversified pipeline includes both small-molecule and biologic drug candidates, as well as companion diagnostic tools.